Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine + interleukin-2
- Development stage
- Unknown
- Lead developer
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
This combination therapy consists of an autologous dendritic cell vaccine and interleukin-2 (IL-2), developed by the Istituto Romagnolo per lo Studio dei Tumori (IRST). The vaccine is produced by harvesting a patient's own dendritic cells and loading them with autologous tumor homogenate, which contains a broad spectrum of patient-specific tumor-associated antigens. This personalized approach aims to prime the immune system to recognize and target residual cancer cells. Following vaccination, IL-2 is administered subcutaneously to act as an immune stimulant, promoting the expansion and activation of cytotoxic T lymphocytes and natural killer cells. The regimen is currently being investigated in a Phase II clinical trial as an adjuvant treatment for patients with resected stage IV rare cancers, specifically head and neck squamous cell carcinoma, neuroendocrine tumors, and soft tissue sarcomas.
- Other names
- Autologous DC vaccine + Interleukin-2DC vaccine + IL-2Autologous DC vaccine loaded with autologous tumour homogenate + Interleukin-2
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on autologous dendritic cell vaccine + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine + interleukin-2.